Related references
Note: Only part of the references are listed.Recommendations from the European Commission Initiative on Breast Cancer for multigene testing to guide the use of adjuvant chemotherapy in patients with early breast cancer, hormone receptor positive, HER-2 negative
Paolo Giorgi Rossi et al.
BRITISH JOURNAL OF CANCER (2021)
70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age
Martine Piccart et al.
LANCET ONCOLOGY (2021)
A nomogram for predicting probability of low risk of MammaPrint results in women with clinically high-risk breast cancer
Young Joo Lee et al.
SCIENTIFIC REPORTS (2021)
Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE)
Stephen R. D. Johnston et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: ASCO Clinical Practice Guideline Update-Integration of Results From TAILORx
Fabrice Andre et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
21-Gene Recurrence Score for prognosis and prediction of taxane benefit after adjuvant chemotherapy plus endocrine therapy: results from NSABP B-28/NRG Oncology
Eleftherios P. Mamounas et al.
BREAST CANCER RESEARCH AND TREATMENT (2018)
Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Focused Update Guideline Summary
Ian Krop et al.
JOURNAL OF ONCOLOGY PRACTICE (2017)
Highlights from the 15th St Gallen International Breast Cancer Conference 15-18 March, 2017, Vienna: tailored treatments for patients with early breast cancer
Consuelo Morigi
ECANCERMEDICALSCIENCE (2017)
Pathology data predicts MammaPrint result- The Magee MammaPrint equation
D. J. Dabbs et al.
CANCER RESEARCH (2016)
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer
F. Cardoso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
MR Imaging Radiomics Signatures for Predicting the Risk of Breast Cancer Recurrence as Given by Research Versions of MammaPrint, Oncotype DX, and PAM50 Gene Assays
Hui Li et al.
RADIOLOGY (2016)
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upaEuro
E. Senkus et al.
ANNALS OF ONCOLOGY (2015)
Breast cancer prognostic classification in the molecular era: the role of histological grade
Emad A. Rakha et al.
BREAST CANCER RESEARCH (2010)
Proliferation is the strongest prognosticator in node-negative breast cancer: significance, error sources, alternatives and comparison with molecular prognostic markers
Jan P. A. Baak et al.
BREAST CANCER RESEARCH AND TREATMENT (2009)
Impact of a national external quality assessment scheme for breast pathology in the UK
IO Ellis et al.
JOURNAL OF CLINICAL PATHOLOGY (2006)
The effect of age, race, tumor size, tumor grade, and disease stage on invasive ductal breast cancer survival in the USSEER database
J Rosenberg et al.
BREAST CANCER RESEARCH AND TREATMENT (2005)
Share Paper
